Clifford Chance has advised the underwriting banks led by Kempen & Co on the successful IPO of Probiodrug AG.  Probiodrug AG with its registered office in Halle, Germany, is a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer's disease.

The IPO included a public offering in the Netherlands as well as private placements in certain member states of the European Union and in Switzerland and a private placement in the United States under Rule 144A. The shares will be listed on the regulated market of the Euronext Amsterdam. The offering volume amounts to approx. EUR 22.5 million. Kempen & Co acted as Sole Global Coordinator and Bookrunner, Petercam as Co-Bookrunner and Close Brothers Seydler as Selling Agent.

The Clifford Chance team was led by partner Markus Pfüller  and consisted of counsel Barbora Moring, associates Sven Kurzawe, Peter Becker and Peter Vlasek as well as transaction lawyer Ksenia Chesnavskaya (all Capital Markets, Frankfurt), partner Dr. Frank Scholderer and senior associates Dr. Michael Lamsa, Oliver Polster and Dr. Anja Döring (all Corporate, Frankfurt), partner Dr. Felix Mühlhäuser and counsel Olaf Mertgen (both Tax, Frankfurt), senior associate Arne Müller (Corporate, Employment and Pension, Düsseldorf) as well as partner Dr. Claudia Milbradt and senior associate Dr. Alexandra Diehl (both Litigation & Dispute Resolution, Düsseldorf).